Ionis Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Ionis Pharmaceuticals, Inc. (IONS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $19.27 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- Ionis Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $19.27M, a 79.55% increase from fiscal 2024.
- Ionis Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $10.73M, a 45.09% decline from fiscal 2023.
- Ionis Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $19.55M, a 39.32% increase from fiscal 2022.
- Ionis Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $14.03M, a 197.25% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $19.27M 10-K · filed 2026-02-26 |
| 2024-12-31 | $10.73M 10-K · filed 2026-02-26 |
| 2023-12-31 | $19.55M 10-K · filed 2026-02-26 |
| 2022-12-31 | $14.03M 10-K · filed 2025-02-19 |
| 2021-12-31 | $4.72M 10-K · filed 2024-02-21 |
| 2020-12-31 | $17.43M 10-K · filed 2023-02-22 |
| 2019-12-31 | -$4.84M 10-K · filed 2022-02-25 |
| 2018-12-31 | -$4.20M 10-K · filed 2021-02-24 |
| 2017-12-31 | -$14.34M 10-K · filed 2020-03-02 |
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
| 2015-12-31 | $0.00 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |